Literature DB >> 17682101

Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.

William W Hope1, Peter A Warn, Andrew Sharp, Paul Reed, Brian Keevil, Arnold Louie, Thomas J Walsh, David W Denning, George L Drusano.   

Abstract

Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17682101      PMCID： PMC2043255          DOI： 10.1128/AAC.00488-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Model appropriateness and population pharmacokinetic modeling.

Authors:  Ene I Ette; Paul J Williams; Yong Ho Kim; James R Lane; Mei-Jen Liu; Edmund V Capparelli
Journal:  J Clin Pharmacol       Date:  2003-06       Impact factor: 3.126

2.  Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.

Authors:  William W Hope; Michael J Kruhlak; Caron A Lyman; Ruta Petraitiene; Vidmantas Petraitis; Andrea Francesconi; Miki Kasai; Diana Mickiene; Tin Sein; Joanne Peter; Amy M Kelaher; Johanna E Hughes; Margaret P Cotton; Catherine J Cotten; John Bacher; Sanjay Tripathi; Louis Bermudez; Timothy K Maugel; Patricia M Zerfas; John R Wingard; George L Drusano; Thomas J Walsh
Journal:  J Infect Dis       Date:  2006-12-21       Impact factor: 5.226

3.  Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.

Authors:  Nathan P Wiederhold; Vincent H Tam; Jingduan Chi; Randall A Prince; Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 4.  The search for synergy: a critical review from a response surface perspective.

Authors:  W R Greco; G Bravo; J C Parsons
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

5.  Population pharmacokinetics of amphotericin B in children with malignant diseases.

Authors:  C E Nath; A J McLachlan; P J Shaw; R Gunning; J W Earl
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

6.  In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.

Authors:  M A Pfaller; S A Messer; L Boyken; H Huynh; R J Hollis; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

7.  Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model.

Authors:  D Andes; T Stamsted; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

8.  In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.

Authors:  D Andes; M van Ogtrop
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi.

Authors:  Brent M Booker; Patrick F Smith; Alan Forrest; Julie Bullock; Pamela Kelchlin; Sujata M Bhavnani; Ronald N Jones; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

10.  Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis.

Authors:  William W Hope; Peter A Warn; Andrew Sharp; Paul Reed; Brian Keevil; Arnold Louie; David W Denning; George L Drusano
Journal:  J Infect Dis       Date:  2005-07-07       Impact factor: 5.226
View more
  3 in total

Review 1.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

Review 2.  Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

Authors:  Kevin J Downes; Brian T Fisher; Nicole R Zane
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

3.  Vertebral infection with Candida albicans failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosine.

Authors:  Line Storm; Karen R Lausch; Maiken C Arendrup; Klaus L Mortensen; Eskild Petersen
Journal:  Med Mycol Case Rep       Date:  2014-07-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.